Double maintains 1 strategies that include CGEM - Cullinan Therapeutics, Inc.
Current Value
$7.551 Year Return
Current Value
$7.551 Year Return
SeekingAlpha
Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data
Yahoo
Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S.Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussionsCash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028CAMBRI
Yahoo
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Tuesday, March 4, 2025,
Yahoo
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Yahoo
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025. The fireside chat is scheduled for Wednesday,
Finnhub
TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass. - Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the REZILIENT1 trial, a Phase 1/2 clinical trial of...
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.21% | $403.24M | 1.43% |
VIXY | -26.21% | $195.31M | 0.85% |
TAIL | -23.27% | $101.24M | 0.59% |
BIL | -14.72% | $46.86B | 0.1356% |
IVOL | -12.20% | $492.66M | 1.02% |
FXY | -11.77% | $726.18M | 0.4% |
XBIL | -10.25% | $727.85M | 0.15% |
TPMN | -9.73% | $30.62M | 0.65% |
BILS | -9.73% | $3.81B | 0.1356% |
SPTS | -9.42% | $6.21B | 0.03% |
UNG | -9.29% | $390.18M | 1.06% |
SGOV | -9.16% | $42.14B | 0.09% |
XONE | -9.15% | $626.27M | 0.03% |
IBTG | -8.83% | $1.84B | 0.07% |
IBTF | -7.62% | $2.18B | 0.07% |
FTSD | -7.37% | $219.44M | 0.25% |
SCHO | -7.32% | $10.77B | 0.03% |
TBLL | -7.06% | $2.44B | 0.08% |
VGSH | -6.95% | $22.84B | 0.03% |
YEAR | -6.57% | $1.31B | 0.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INSM | <0.01% | $11.78B | +126.93% | 0.00% |
ABT | 0.05% | $215.92B | +11.71% | 1.79% |
CWST | -0.08% | $7.22B | +17.31% | 0.00% |
OCFT | 0.10% | $207.88M | +178.33% | 0.00% |
CORT | -0.10% | $7.15B | +184.34% | 0.00% |
NGG | 0.12% | $64.24B | +1.44% | 5.26% |
MSDL | 0.14% | $1.60B | -13.17% | 10.93% |
ADC | -0.16% | $7.83B | +28.55% | 4.14% |
DXCM | -0.26% | $26.39B | -51.80% | 0.00% |
BF.A | 0.28% | $15.65B | -35.99% | 2.67% |
PRT | -0.29% | $43.92M | -13.84% | 12.40% |
CYCN | -0.33% | $6.94M | -16.05% | 0.00% |
FMTO | 0.34% | $324.60K | -99.77% | 0.00% |
TU | -0.38% | $21.83B | -10.88% | 7.82% |
MNOV | 0.40% | $62.29M | -18.59% | 0.00% |
HLN | -0.40% | $43.48B | +17.87% | 0.53% |
CIG.C | 0.43% | $2.26B | +4.19% | 0.00% |
MDLZ | 0.44% | $85.48B | -1.20% | 2.75% |
ALL | 0.45% | $50.56B | +15.20% | 1.97% |
LITB | 0.47% | $35.12M | -56.39% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -17.13% | $21.99B | +18.32% | 1.16% |
AEP | -14.04% | $57.43B | +24.47% | 3.50% |
CME | -13.51% | $93.12B | +21.44% | 4.05% |
ABBV | -13.19% | $308.16B | +3.99% | 3.62% |
ED | -12.71% | $39.01B | +22.30% | 3.10% |
SJW | -12.66% | $1.76B | -3.30% | 3.12% |
AMT | -12.09% | $97.52B | +16.61% | 3.11% |
AON | -10.96% | $79.71B | +18.66% | 0.73% |
SO | -10.60% | $97.49B | +27.75% | 3.23% |
EXC | -10.47% | $45.55B | +22.61% | 3.41% |
MO | -9.83% | $95.08B | +36.09% | 7.13% |
XEL | -9.49% | $39.31B | +27.89% | 3.24% |
DUK | -9.08% | $90.79B | +22.62% | 3.56% |
AWK | -9.04% | $27.92B | +21.50% | 2.13% |
WEC | -8.55% | $33.32B | +32.90% | 3.23% |
CCI | -8.34% | $41.44B | -1.98% | 6.57% |
FE | -8.23% | $23.14B | +6.57% | 4.24% |
WRB | -7.95% | $25.45B | +24.81% | 0.54% |
VSA | -7.63% | $3.39M | -81.40% | 0.00% |
KNSL | -7.58% | $11.15B | +5.61% | 0.13% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BWX | -0.02% | $1.03B | 0.35% |
FMB | 0.03% | $1.90B | 0.65% |
MLN | -0.04% | $514.10M | 0.24% |
CGMU | -0.06% | $2.94B | 0.27% |
MUB | -0.08% | $38.00B | 0.05% |
HYMB | -0.09% | $2.53B | 0.35% |
UTEN | -0.12% | $193.60M | 0.15% |
BOND | -0.14% | $5.45B | 0.7% |
PZA | 0.19% | $2.77B | 0.28% |
WEAT | 0.19% | $121.87M | 0.28% |
FXE | 0.19% | $300.52M | 0.4% |
JPLD | -0.22% | $1.16B | 0.24% |
JMUB | -0.24% | $2.58B | 0.18% |
IBD | -0.24% | $397.12M | 0.44% |
USDU | 0.28% | $216.58M | 0.5% |
USO | -0.30% | $979.36M | 0.6% |
UUP | 0.31% | $258.38M | 0.77% |
BNO | 0.32% | $80.49M | 1% |
LGOV | -0.32% | $679.81M | 0.67% |
JPST | 0.33% | $29.86B | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWC | 43.20% | $747.43M | 0.6% |
XBI | 42.63% | $4.92B | 0.35% |
ARKG | 40.83% | $959.87M | 0.75% |
IWO | 40.62% | $10.46B | 0.24% |
GNOM | 40.05% | $46.24M | 0.5% |
IWM | 38.92% | $60.51B | 0.19% |
PBW | 38.75% | $196.77M | 0.65% |
VTWO | 38.74% | $10.64B | 0.07% |
KOMP | 38.60% | $1.94B | 0.2% |
GSSC | 38.14% | $489.81M | 0.2% |
KJUL | 38.12% | $131.84M | 0.79% |
KJAN | 38.08% | $300.51M | 0.79% |
SCHA | 37.12% | $15.29B | 0.04% |
PSC | 37.09% | $678.81M | 0.38% |
PTH | 36.88% | $101.34M | 0.6% |
ISCG | 36.81% | $627.41M | 0.06% |
PBE | 36.69% | $215.97M | 0.58% |
KAPR | 36.58% | $167.86M | 0.79% |
VBK | 36.42% | $16.64B | 0.07% |
IBB | 35.99% | $5.33B | 0.45% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EXPO | 49.87% | $4.01B | -1.09% | 1.46% |
ULH | 43.34% | $700.30M | -21.30% | 1.60% |
BDTX | 38.05% | $80.46M | -74.51% | 0.00% |
IDYA | 37.74% | $1.38B | -63.71% | 0.00% |
DNLI | 37.63% | $1.82B | -34.79% | 0.00% |
MOG.A | 37.44% | $5.05B | +0.14% | 0.72% |
KALU | 36.78% | $841.57M | -42.72% | 5.75% |
IBRX | 36.65% | $2.10B | -59.41% | 0.00% |
BEAM | 36.35% | $1.46B | -46.35% | 0.00% |
SNAP | 36.35% | $13.28B | -31.07% | 0.00% |
DAWN | 36.27% | $685.16M | -51.92% | 0.00% |
SYRE | 35.72% | $718.87M | -69.09% | 0.00% |
PLAB | 35.28% | $1.13B | -38.14% | 0.00% |
NNOX | 34.89% | $256.82M | -58.23% | 0.00% |
CRBU | 34.87% | $79.94M | -80.15% | 0.00% |
VIK | 34.30% | $17.36B | +63.42% | 0.00% |
ETN | 34.28% | $106.06B | -14.67% | 1.43% |
AN | 34.27% | $6.53B | +8.43% | 0.00% |
GPRO | 34.24% | $75.75M | -74.40% | 0.00% |
RXRX | 34.21% | $1.81B | -49.44% | 0.00% |